Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.


Reference number
Coordinator SPAGO NANOMEDICAL AB (PUBL) - Spago Nanomedical AB
Funding from Vinnova SEK 500 000
Project duration May 2018 - November 2018
Status Completed

Purpose and goal

The objective of this project is to develop a business plan that includes a road map for the clinical development and subsequent commercialisation of SpagoPix. The objectives of the project include an assessment of the technical and market feasibility of commercialising new nanomaterial-based tumour selective MRI agent, SpagoPix.

Expected results and effects

Spago Nanomedical has analysed market data and conducted interviews with potential partners/KOLs. We have gained insights into market conditions including competitive landscape, challenges and opportunities of SpagoPix, and a deeper knowledge of the user needs, potential partners and stakeholders and how to reach them. We have developed a business plan guiding the clinical validation and commercialization efforts. The strategy is to perform a FIH-study for SpagoPix and thereafter acquire a strategic partner for continued clinical studies and commercialization.

Planned approach and implementation

The feasibility assessment has been performed using Strategic Business Planning Methodology - Strategic Business Review analysing market and competition, mapping out the value proposition for customers and defining clinical, economic and regulatory requirements to be considered in the Phase 2 Project. - Business Model Visioning developing the business model in line with the company’s vision, values, long-term development and revenue goals. - Business Plan Development and Formulation formulation of the final business strategy, business model and commercialisation plan.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 21 December 2018

Reference number 2018-02240

Page statistics